' Little Merit ' in Sublingual Buprenorphine for Pain, Says FDA Panel ' Little Merit ' in Sublingual Buprenorphine for Pain, Says FDA Panel
The FDA advisory committee voted overwhelmingly against the approval of a sublingual form of buprenorphine for treating moderate-to-severe acute pain, citing weak efficacy and safety concerns.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news